MARK ADELMAN

oppose market basket increase in IPPS rule, support proposed rule on medicare aco payment incorporating catheter billing fraud for incentive payments, support increase in CHGME and GME funding and training slots, oppose 340B impacts from pharmaceutical company actions re: contract pharmacies, support increases in Medicare reimbursements, DSH delays and legislation increasing GME slots and physician/workforce initiatives. Seek relief on ACO/Catheter fraud issue. oppose site neutral cuts, expanding medicare telehealth, increase NIH funding, support employee retention credit timeframes, and provide targeted support for improving hospital discharges, oppose market basket reimbursement rates in Medicare proposed rules, support 340B contract pharmacy 340B PATIENTS Act.

oppose market basket increase in IPPS rule, oppose medicare aco payment without incorporating catheter billing fraud for incentive payments, support increase in CHGME and GME funding and training slots, oppose 340B impacts from pharmaceutical company actions re: contract pharmacies, support increases in Medicare reimbursements, DSH delays and legislation increasing GME slots and physician/workforce initiatives. Seek relief on ACO/Catheter fraud issue. oppose site neutral cuts, expanding medicare telehealth, increase NIH funding, support employee retention credit timeframes, and provide targeted support for improving hospital discharges, oppose market basket reimbursement rates in Medicare proposed rules, support 340B contract pharmacy 340B PATIENTS Act.

oppose market basket increase in IPPS rule, oppose medicare aco payment without incorporating catheter billing fraud for incentive payments, support increase in CHGME and GME funding and training slots, oppose 340B impacts from pharmaceutical company actions re: contract pharmacies, support increases in Medicare reimbursements, DSH delays and legislation increasing GME slots and physician/workforce initiatives. oppose site neutral cuts, expanding medicare telehealth, increase NIH funding, support employee retention credit timeframes, and provide targeted support for improving hospital discharges, oppose market basket reimbursement rates in Medicare proposed rules, support 340B contract pharmacy 340B PATIENTS Act.

oppose DEA proposed rules on prescription drugs for behavioral health, support increase in CHGME and GME funding and training slots, oppose 340B impacts from pharmaceutical company actions re: contract pharmacies, support increases in Medicare reimbursements, DSH delays and legislation increasing GME slots and physician/workforce initiatives (e.g., HR2389). oppose site neutral cuts, expanding medicare telehealth, increase NIH funding, support employee retention credit timeframes, and provide targeted support for improving hospital discharges, oppose market basket reimbursement rates in Medicare proposed rules, support 3.021 (pulmonary rehab telehealth).

BROWN UNIVERSITY HEALTH (FKA LIFESPAN)

BROWN UNIVERSITY HEALTH (FKA LIFESPAN)

BROWN UNIVERSITY HEALTH (FKA LIFESPAN)

BROWN UNIVERSITY HEALTH (FKA LIFESPAN)